Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 31Genitourinary 9Thoracic 8Head & Neck 4Gynecologic 4CNS 4Tumor-Agnostic 3Gastrointestinal 2Other solid neoplasm 1Endocrine 1

Conditions

Neoplasm Metastasis 2Neoplasms 1

Interventions

Gemcitabine 26Paclitaxel 24pembrolizumab 23Carboplatin 22Bevacizumab 18Radiotherapy 16Oxaliplatin 16Erlotinib Hydrochloride 16Nivolumab 15Cisplatin 14Capecitabine 14Fluorouracil 13Trastuzumab 12Docetaxel 12atezolizumab 11Magnetic Resonance Spectroscopy 11Leucovorin 11Cyclophosphamide 11Irinotecan 10Ipilimumab 10Vemurafenib 9Everolimus 9Cetuximab 9cabozantinib 8Radiosurgery 8Afatinib 8130-nm albumin-bound paclitaxel 8trametinib 7lenvatinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × sacituzumab govitecan × Tumor-Agnostic × Clear all
NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03964727 2026-04-28

TROPiCS-03

Gilead Sciences

Phase 2 Active not recruiting
227 enrolled 31 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT05097599 2025-01-08

StrataPATH

Strata Oncology

Phase 2 Terminated
11 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡